Celularity Inc. entered into a $1,000,000 secured loan agreement with the Philip & Daniele Barach Family Trust on June 29, 2026, bearing 4.0% interest per annum, which increases to 18.0% upon default. The loan is secured by a first-priority security interest in substantially all of the Company's personal property and matures upon receipt of gross proceeds from certain financing or strategic transactions. Additionally, Vincent LeVien resigned from the Board of Directors effective June 26, 2026. Celularity Inc. is a biotechnology company focused on developing cell therapy products.

Celularity Inc. appointed Steven N. Gordon, Esq. as Chief Operating and Administrative Officer and a member of the Board of Directors, and K. Harold Fletcher, Esq. as Chief Legal and Strategy Officer and Corporate Secretary, both effective June 19, 2026. Celularity Inc. is a biotechnology company that develops and manufactures advanced cell therapy products.

On June 9, 2026, Celularity Inc. received notice from Nasdaq that it failed to meet the minimum Market Value of Listed Securities (MVLS) requirement of $35 million for 30 consecutive business days. The company has until December 7, 2026, to regain compliance by maintaining a market value of at least $35 million for 10 consecutive business days or by increasing stockholders' equity to at least $2.5 million. Failure to comply may result in delisting from the Nasdaq Capital Market. Celularity Inc. is a biotechnology company focused on developing cell therapies.